Allocation to SGLT-2 inhibitors reduced the risk of AKI by 30% compared to placebo (0.70, 0.62-0.79; 1013 events), and there was no evidence the RRs varied between or within trial populations (all het test p>0.05). This evidence concerns the gene SLC5A2 and acute kidney injury.